| Bioactivity | SR17018 is an mu-opioid-receptor (MOR) agonist, binding with GTPγS, with an EC50 of 97 nM. | ||||||||||||
| Target | EC50: 97 nM (MOR) | ||||||||||||
| Invitro | SR17018 is an mu-opioid-receptor (MOR) agonist, binding with GTPγS, with an EC50 of 97 nM. SR17018 shows no obvious effect on inducing βarrestin2 recruitment to the MOR at below 10 μM. SR17018 promotes signaling through G proteins or βarrestin2[1]. | ||||||||||||
| Name | SR17018 | ||||||||||||
| CAS | 2134602-45-0 | ||||||||||||
| Formula | C19H18Cl3N3O | ||||||||||||
| Molar Mass | 410.72 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Schmid CL, et al. Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics. Cell. 2017 Nov 16;171(5):1165-1175.e13. |